2 news items
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
INVA
8 May 24
for intravenous use: targeted antibacterial for patients with HABP/VABP caused by Acinetobacter
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
ARMP
INVA
4 Mar 24
transaction will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused
- Prev
- 1
- Next